Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International journal of impotence research

• Publication date

  2008-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ijir.2008.4PMID 18418391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of Cyclic Nucleotide Levels by Sequestration

  2010cited by this paper
• Guanosine 3',5'-cyclic monophosphate (cGMP)/cGMP-dependent protein kinase induce interleukin-6 transcription in osteoblasts.

  2007cited by this paper
• Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling.

  2007cited by this paper
• Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

  2007cited by this paper
• Conversion of Phosphodiesterase-5 (PDE5) Catalytic Site to Higher Affinity by PDE5 Inhibitors

  2007cited by this paper
• PDE5 inhibitors beyond erectile dysfunction

  2007cited by this paper
• Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.

  2006cited by this paper
• Phosphodiesterase 5: Molecular Characteristics Relating to Structure, Function, and Regulation

  2006cited by this paper
• Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.

  2006cited by this paper
• The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy

  2006cited by this paper
• Cyclic Nucleotide Phosphodiesterases in Health and Disease

  2006cited by this paper
• Role of cyclic GMP in gene regulation.

  2005cited by this paper
• The Biology of Cyclic GMP-dependent Protein Kinases*

  2005cited by this paper
• Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis.

  2005cited by this paper
• STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G.

  2005cited by this paper
• Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.

  2005cited by this paper
• Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.

  2005cited by this paper
• The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

  2005cited by this paper
• Duration of action of sildenafil citrate in men with erectile dysfunction.

  2004cited by this paper
• Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window.

  2004cited by this paper
• Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

  2004cited by this paper
• Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil.

  2004cited by this paper
• ERK7 Expression and Kinase Activity Is Regulated by the Ubiquitin-Proteosome Pathway*

  2004cited by this paper
• Allosteric sites of phosphodiesterase-5 sequester cyclic GMP.

  2004cited by this paper
• Blockade of maitotoxin-induced endothelial cell lysis by glycine and L-alanine.

  2003cited by this paper
• Phosphodiesterase 5 inhibitors in male sexual dysfunction

  2003cited by this paper
• [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.

  2003cited by this paper
• cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5.

  2003cited by this paper
• Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA.

  2003cited by this paper
• Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists

  2003cited by this paper
• Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

  2003cited by this paper
• Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction.

  2003cited by this paper
• Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase.

  2002cited by this paper
• Nitric oxide regulation of penile erection: biology and therapeutic implications.

  2002cited by this paper
• PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS

  2002cited by this paper
• A Conserved Serine Juxtaposed to the Pseudosubstrate Site of Type I cGMP-dependent Protein Kinase Contributes Strongly to Autoinhibition and Lower cGMP Affinity*

  2002cited by this paper
• Phosphorylation of Isolated Human Phosphodiesterase-5 Regulatory Domain Induces an Apparent Conformational Change and Increases cGMP Binding Affinity*

  2002cited by this paper
• Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.

  2001cited by this paper
• Allosteric sites of phosphodiesterase-5 (PDE5)

  2001cited by this paper
• Phosphodiesterase inhibitors in the treatment of erectile dysfunction.

  2000cited by this paper
• Mechanisms of NO/cGMP-dependent vasorelaxation.

  2000cited by this paper
• Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.

  2000cited by this paper
• Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

  1999cited by this paper
• Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.

  1999cited by this paper
• Cyclic GMP Phosphodiesterase-5: Target of Sildenafil*

  1999cited by this paper
• Phosphodiesterase inhibitors in the treatment of erectile dysfunction.

  1998cited by this paper
• Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases.

  1998cited by this paper
• Activation by Autophosphorylation or cGMP Binding Produces a Similar Apparent Conformational Change in cGMP-dependent Protein Kinase*

  1998cited by this paper
• Activation of Protein Kinase C Triggers Its Ubiquitination and Degradation

  1998cited by this paper
• Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.

  1998cited by this paper
• Potential Roles of Conserved Amino Acids in the Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)*

  1998cited by this paper
• Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

  1996cited by this paper
• Autophosphorylation of Type Iβ cGMP-dependent Protein Kinase Increases Basal Catalytic Activity and Enhances Allosteric Activation by cGMP or cAMP*

  1996cited by this paper
• Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity.

  1996cited by this paper
• Cyclic guanosine monophosphate-dependent protein kinase is targeted to intermediate filaments and phosphorylates vimentin in A23187-stimulated human neutrophils.

  1995cited by this paper
• Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries.

  1992cited by this paper
• Vimentin is transiently co-localized with and phosphorylated by cyclic GMP-dependent protein kinase in formyl-peptide-stimulated neutrophils.

  1991cited by this paper
• Compartmentalization of cyclic GMP-dependent protein kinase in formyl-peptide stimulated neutrophils.

  1990cited by this paper
• Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase.

  1990cited by this paper
• Interconvertible cGMP-free and cGMP-bound forms of cGMP-dependent protein kinase in mammalian tissues.

  1987cited by this paper
• cGMP-dependent protein kinase. Autophosphorylation changes the characteristics of binding site 1.

  1985cited by this paper
• Toxicokinetics of [14C]hexafluoroacetone in the rat.

  1984cited by this paper
• Studies of two different intrachain cGMP-binding sites of cGMP-dependent protein kinase.

  1983cited by this paper
• Autophosphorylation of cGMP‐dependent protein kinase is stimulated only by occupancy of one the two cGMP binding sites

  1983cited by this paper
• The quantitative relationship between intracellular concentration and egress of cyclic AMP from cultured cells.

  1981cited by this paper
• Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase.

  1978cited by this paper
• On the significance of the retention of ligand by protein.

  1975cited by this paper
• Release of glucose from purified galactose-binding protein of Escherichia coli upon addition of galactose.

  1974cited by this paper
• Purification and properties of a ribose-binding protein from Escherichia coli.

  1974cited by this paper
• Acute toxicity of some perhalogenated acetones.

  1965cited by this paper
• highlighted topics Signal Transduction in Smooth Muscle Invited Review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression

  year unknowncited by this paper

• The role of patent analysis in target selection

  2025cites this paper
• Heterocyclic Nitrogen Compounds as Potential PDE4B Inhibitors in Activated Macrophages

  2024cites this paper
• The Combination of Oolonghomobisflavan B and Diallyl Disulfide Induces Apoptotic Cell Death via 67-kDa Laminin Receptor/Cyclic Guanosine Monophosphate in Acute Myeloid Leukemia Cells

  2024cites this paper
• Phosphodiesterase 5 Inhibitor Potentiates Epigallocatechin 3-O-Gallate-Induced Apoptotic Cell Death via Activation of the cGMP Signaling Pathway in Caco-2 Cells

  2022cites this paper
• Ameliorative Sexual Behavior and Phosphodiesterase-5 Inhibitory Effects of Spondias mangifera Fruit Extract in Rodents: In Silico, In Vitro, and In Vivo Study

  2022cites this paper
• Effect of Low-Dose Tadala l Once Daily On Glycemic Control In Patients With Type 2 Diabetes and Erectile Dysfunction: A Randomized, Double- blind, Placebo-controlled Pilot Study

  2021cites this paper
• Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study

  2021cites this paper
• A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation.

  2021cites this paper
• Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.

  2020cites this paper
• A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP

  2020cites this paper
• Silencing Nogo-B receptor inhibits penile corpus cavernosum vascular smooth muscle cell apoptosis of rats with diabetic erectile dysfunction by down-regulating ICAM-1

  2019cites this paper
• Effect of co-administration of BRL-37344 and tadalafil on reduction of overactive bladder symptoms after induction of detrusor overactivity in mice 1

  2019cites this paper
• Editorial Comment to Tadalafil improves bladder dysfunction and object recognition in rats with pelvic venous congestion

  2019cites this paper
• Tadalafil improves bladder dysfunction and object recognition in rats with pelvic venous congestion

  2019cites this paper
• Developing a phosphodiesterase-5 inhibitor assay to detect counterfeit drugs containing phosphodiesterase-5 inhibitors using spectrophotometry

  2019cites this paper
• The effect of phosphodiesterase-5 inhibitor, tadalafil, on in vitro potassium chloride-induced contractions of isolated human ureteral tissue

  2018cites this paper
• Surface Binding Energy Landscapes Affect Phosphodiesterase Isoform-Specific Inhibitor Selectivity

  2018cites this paper
• Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair

  2017cites this paper
• Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets

  2017cites this paper
• Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study

  2017cites this paper
• Comparison of Pharmacokinetics of Vardenafil Administered Using an Ultrasonic Nebulizer for Inhalation vs a Single 10-mg Oral Tablet.

  2016cites this paper
• Pharmacology of drugs used for the treatment of erectile dysfunction

  2016cites this paper
• PERFORMANCE EVALUATION OF DIFFERENT HPLC COLUMNS IN SILDENAFIL AND TADALAFIL ANALYSIS

  2015influential citation
• Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

  2015cites this paper
• The VO(2)-on kinetics in constant load exercise sub-anaerobic threshold reflects endothelial function and dysfunction in muscle microcirculation.

  2015cites this paper
• Review of erectile dysfunction in diabetic animal models.

  2014cites this paper
• Clinical and molecular genetics of the phosphodiesterases (PDEs).

  2014cites this paper
• Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa

  2012influential citation
• Combined effect of sildenafil and guanethidine, propranolol or verapamil on erectile function in rats

  2012cites this paper
• Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

  2012cites this paper
• Activation of muscarinic receptors inhibits neurogenic nitric oxide in the corpus cavernosum.

  2012cites this paper
• Validated HPLC Method for Determination of Sildenafil in Pharmaceutical Dosage Forms

  2011cites this paper
• Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action.

  2011cites this paper
• Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction

  2011influential citation
• Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.

  2011cites this paper
• PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study

  2011cites this paper
• Performance evaluation of different HPLC columns in sildenafil and tadanafil analysis

  2011cites this paper
• A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

  2010cites this paper
• MULTIPLE AFFINITY STATES OF cGMP-SPECIFIC PDE (PDE5) FOR SILDENAFIL INHIBITION DEFINED BY cGMP-DEPENDENT AND cGMP-INDEPENDENT MECHANISMS

  2010cites this paper
• Multiple Affinity States of cGMP-Specific Phosphodiesterase for Sildenafil Inhibition Defined by cGMP-Dependent and cGMP-Independent Mechanisms

  2010cites this paper
• Distinct Allostery Induced in the Cyclic GMP-binding, Cyclic GMP-specific Phosphodiesterase (PDE5) by Cyclic GMP, Sildenafil, and Metal Ions*

  2010cites this paper
• Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.

  2010cites this paper
• cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

  2010cites this paper
• Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial.

  2010cites this paper
• Molecular mechanisms of penile erection.

  2010cites this paper
• Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds

  2009cites this paper
• Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case

  2009cites this paper
• Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study.

  2009influential citation
• 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.

  2009cites this paper
• Current Opinion in Oncology. Current world literature.

  2009cites this paper
• The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease.

  2008cites this paper